Chemoradiotherapy of head and neck cancer - Can the bumble bee fly?

Radiotherapy and Oncology

Volumn 92, Issue 1, 2009, Pages 1-3

  Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; EDITORIAL; EVIDENCE BASED PRACTICE; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT;

COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 66949114269     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.06.001     Document Type: Editorial

References (29)

1. Tannock I.F. Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol 16 (1989) 83-101
2. Steel GG, editor. Basic clinical radiobiology. London: Edward Arnold; 1993.
3. Pignon JP, Maître AL, Maillard E, Bourhis J. On behalf of the MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009:92;4-14.
4. Bourhis J., Overgaard J., Audry H., Ang K.K., Saunders M., Bernier J., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 (2006) 843-854
5. Baujat B., Audry H., Bourhis J., Chan A.T., Onat H., Chua D.T., et al. MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 (2006) 47-56
6. Pignon J.P., Bourhis J., Domenge C., and Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
7. Henk J.M. Concomitant chemoradiation for head and neck cancer: saving lives or grays?. Clin Oncol (R Coll Radiol) 13 (2001) 333-335
8. Machtay M., Moughan J., Trotti A., Garden A.S., Weber R.S., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26 (2008) 3582-3589
9. Bentzen S.M., and Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25 (2007) 4096-4103
10. Piccirillo J.F., Tierney R.M., Costas I., Grove L., and Spitznagel Jr. E.L. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291 (2004) 2441-2447
11. Adelstein D.J., Li Y., Adams G.L., Wagner Jr. H., Kish J.A., Ensley J.F., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
12. Corvò R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 85 (2007) 156-170
13. Thomas G.M. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med 340 (1999) 1198-1200
14. Peters L.J., Ang K.K., and Thames Jr. H.D. Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol 27 (1988) 185-194
15. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
16. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25 (2007) 4066-4074
17. Grau C., and Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13 (1988) 301-309
18. Grau C., Agarwal J.P., Jabeen K., Rab Khan A., Abeyakoon S., Hadjieva T., et al. Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol 67 (2003) 17-26
19. Overgaard J., Hansen H.S., Specht L., Overgaard M., Grau C., Andersen E., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362 (2003) 933-940
20. Hansen O., Overgaard J., Hansen H.S., Overgaard M., Höyer M., Jörgensen K.E., et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol 43 (1997) 47-51
21. Eriksen J.G., Buffa F.M., Alsner J., Steiniche T., Bentzen S.M., and Overgaard J. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother Oncol 72 (2004) 275-282
22. Bastholt L., Specht L., Jensen K., Brun E., Loft A., Petersen J., et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 85 (2007) 24-28
23. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
24. Mydin A.R., and Armstrong J.G. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol 85 (2007) 171
25. Giro C., Berger B., Bölke E., Ciernik I.F., Duprez F., Locati L., et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in headand neck cancer: results of a survey in EORTC institutes. Radiother Oncol 90 (2009) 166-171
26. Pryor D.I., Porceddu S.V., Burmeister B.H., Guminski A., Thomson D.B., Shepherdson K., et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90 (2009) 172-176
27. Eriksen J.G., and Overgaard M. Late onset of skin toxicity induced by EGFr-inhibitors. Adiother Oncol 90 (2009) 280-281
28. Lassen P., Eriksen J.G., Hamilton-Dutoit S., Tramm T., Alsner J., and Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 27 (2009) 1992-1998
29. Bernier J. Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol 19 (2009) 3-10